Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation

Decreased autophagy is accompanied by the development of a myeloproliferative state or acute myeloid leukemia (AML). AML cells are often sensitive to autophagy-inducing stimuli, prompting the idea that targeting autophagy can be useful in AML cytotoxic therapy. AML NB4 cells overexpressing microtubule-associated protein 1 light chain 3-green fluorescent protein were screened with 69 inhibitors to analyze autophagy activity. AML cells were treated with the polo-like kinase 1 (PLK1) inhibitors RO3280 and BI2536 before autophagy analysis. Cleaved LC3 (LC3-II) and the phosphorylation of mammalian target of rapamycin (mTOR), adenosine monophosphate-activated protein kinase, and Unc-51-like kinase 1 during autophagy was detected with western blotting. Autophagosomes were detected using transmission electron microscopy. Several inhibitors had promising autophagy inducer effects: BI2536, MLN0905, SK1-I, SBE13 HCL and RO3280. Moreover, these inhibitors all targeted PLK1. Autophagy activity was increased in the NB4 cells treated with RO3280 and BI2536. Inhibition of PLK1 expression in NB4, K562 and HL-60 leukemia cells with RNA interference increased LC3-II and autophagy activity. The phosphorylation of mTOR was reduced significantly in NB4 cells treated with RO3280 and BI2536, and was also reduced significantly when PLK1 expression was downregulated in the NB4, K562 and HL-60 cells. We demonstrate that PLK1 inhibition induces AML cell autophagy and that it results in mTOR dephosphorylation. These results may provide new insights into the molecular mechanism of PLK1 in regulating autophagy.

[1]  Jing Wang,et al.  Overexpression of PLK3 Mediates the Degradation of Abnormal Prion Proteins Dependent on Chaperone-Mediated Autophagy , 2016, Molecular Neurobiology.

[2]  R. Davis,et al.  Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia. , 2016, Blood.

[3]  K. Coombes,et al.  MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells , 2016, Oncotarget.

[4]  R. Dempsey,et al.  Poststroke Induction of α-Synuclein Mediates Ischemic Brain Damage , 2016, The Journal of Neuroscience.

[5]  N. Ahmad,et al.  Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics , 2016, Molecular Cancer Therapeutics.

[6]  W. Gu,et al.  Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis , 2016, International journal of nanomedicine.

[7]  L. Gachkar,et al.  Expression analysis of BECN1 in acute myeloid leukemia: association with distinct cytogenetic and molecular abnormalities , 2016, International journal of laboratory hematology.

[8]  M. Wetzler,et al.  Polo-like kinase inhibitors in hematologic malignancies. , 2016, Critical reviews in oncology/hematology.

[9]  K. Stegmaier,et al.  Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML , 2015, Oncogene.

[10]  N. Hamdy,et al.  Beclin-1 and hypoxia-inducible factor-1α genes expression: Potential biomarkers in acute leukemia patients. , 2016, Cancer biomarkers : section A of Disease markers.

[11]  Wen-Qi Jiang,et al.  Puquitinib mesylate (XC-302) induces autophagy via inhibiting the PI3K/AKT/mTOR signaling pathway in nasopharyngeal cancer cells , 2015, International journal of molecular medicine.

[12]  Qiang Shi,et al.  Activation of the AMPK-ULK1 pathway plays an important role in autophagy during prion infection , 2015, Scientific Reports.

[13]  D. Ferguson,et al.  Autophagy limits proliferation and glycolytic metabolism in acute myeloid leukemia , 2015, Cell Death Discovery.

[14]  V. Kota,et al.  Volasertib for AML: clinical use and patient consideration , 2015, OncoTargets and therapy.

[15]  J. Cheong,et al.  Induction of cytosine arabinoside-resistant human myeloid leukemia cell death through autophagy regulation by hydroxychloroquine. , 2015, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[16]  I. Ganley,et al.  Pharmacological Inhibition of ULK1 Kinase Blocks Mammalian Target of Rapamycin (mTOR)-dependent Autophagy* , 2015, The Journal of Biological Chemistry.

[17]  Nazanin Heidari,et al.  Targeting PI3K/AKT/mTOR network for treatment of leukemia , 2015, Cellular and Molecular Life Sciences.

[18]  Chunyan Sun,et al.  [Expression of autophagy related gene BECLIN-1 and number of autophagic vacuoles in bone marrow mononuclear cells from 40 myelodysplastic syndromes patients and their significance]. , 2015, Zhongguo shi yan xue ye xue za zhi.

[19]  Huiting Zhou,et al.  Molecular Targeting of the Oncoprotein PLK1 in Pediatric Acute Myeloid Leukemia: RO3280, a Novel PLK1 Inhibitor, Induces Apoptosis in Leukemia Cells , 2015, International journal of molecular sciences.

[20]  P. Schöffski,et al.  Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy , 2014, Leukemia.

[21]  D. Moon,et al.  Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells. , 2014, Anticancer research.

[22]  Xiaoying Lin,et al.  YY1-MIR372-SQSTM1 regulatory axis in autophagy , 2014, Autophagy.

[23]  E. V. Van Bockstaele,et al.  Suppression of MAPK/JNK-MTORC1 signaling leads to premature loss of organelles and nuclei by autophagy during terminal differentiation of lens fiber cells , 2014, Autophagy.

[24]  J. McCubrey,et al.  Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia , 2013, Expert opinion on therapeutic targets.

[25]  Zhe Zhang,et al.  Polo-like kinase 1 is overexpressed in renal cancer and participates in the proliferation and invasion of renal cancer cells , 2013, Tumor Biology.

[26]  S. Milstien,et al.  A specific sphingosine kinase 1 inhibitor attenuates airway hyperresponsiveness and inflammation in a mast cell-dependent murine model of allergic asthma. , 2013, The Journal of allergy and clinical immunology.

[27]  Emmanuel Barillot,et al.  Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer. , 2013, Cancer research.

[28]  N. Eissa,et al.  Plk1 is upregulated in androgen-insensitive prostate cancer cells and its inhibition leads to necroptosis , 2012, Oncogene.

[29]  Q. Zhan,et al.  Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells. , 2012, Gastroenterology.

[30]  A. Isacchi,et al.  NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies , 2012, Molecular Cancer Therapeutics.

[31]  Yi Chen,et al.  Identification of novel, potent and selective inhibitors of Polo-like kinase 1. , 2012, Bioorganic & Medicinal Chemistry Letters.

[32]  T. Kawamoto,et al.  TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens , 2011, Molecular Cancer Therapeutics.

[33]  F. Berthold,et al.  Polo-Like Kinase 1 is a Therapeutic Target in High-Risk Neuroblastoma , 2010, Clinical Cancer Research.

[34]  A. Abdollahi,et al.  Phenotype-assisted transcriptome analysis identifies FOXM1 downstream from Ras–MKK3–p38 to regulate in vitro cellular invasion , 2010, Oncogene.

[35]  Christian Bailly,et al.  Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. , 2009, Blood.

[36]  F. Callera,et al.  Lack of antileukemic activity of rapamycin in elderly patients with acute myeloid leukemia evolving from a myelodysplastic syndrome. , 2008, Leukemia research.

[37]  M. Barbacid,et al.  Cell cycle kinases in cancer. , 2007, Current opinion in genetics & development.

[38]  Kiranmai Gumireddy,et al.  ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. , 2005, Cancer cell.

[39]  Xiaoqi Liu,et al.  Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.